Repligen completes acquisition of BioLife Solutions in cash and stock deal

Repligen Corporation (NASDAQ: RGEN) said on Monday it completed its previously announced acquisition of BioLife Solutions, Inc., a developer and supplier of cell processing tools and services for the cell and gene therapy market.

Under the terms of the agreement, BioLife stockholders received $11.25 per share in cash and 0.1442 shares of Repligen common stock, with cash paid in lieu of any fractional shares. The transaction closed on Oct. 6, 2026.

"We are excited to welcome BioLife team members to Repligen," Olivier Loeillot, President and Chief Executive Officer of Repligen, said in a statement. "BioLife's highly-differentiated portfolio of products expands our presence in the rapidly growing cell therapy market, adding a deeply embedded, high-margin consumables business with attractive recurring revenue."

In connection with the merger, all outstanding options, restricted stock units, and performance-based restricted stock units of BioLife accelerated and vested in full prior to the effective time, converting automatically into the right to receive the merger consideration. BioLife has ceased to exist as a separate legal entity and requested that The Nasdaq Capital Market suspend trading of its common stock and file a Form 25 to delist and deregister the shares.

Perella Weinberg Partners LP and Goldman Sachs & Co. LLC served as financial advisors and Goodwin Procter LLP served as legal counsel to Repligen. Centerview Partners, LLC served as financial advisor and K&L Gates LLP served as legal counsel to BioLife.

Repligen said it intends to provide additional detail regarding the transaction's expected impact on its 2026 financial outlook during its upcoming third quarter 2026 earnings call.